Corcept Therapeutics Incorporated Stock Fundamentals
| CORT Stock | USD 49.90 0.49 0.97% |
Corcept Therapeutics Incorporated fundamentals help investors to digest information that contributes to Corcept Therapeutics' financial success or failures. It also enables traders to predict the movement of Corcept Stock. The fundamental analysis module provides a way to measure Corcept Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corcept Therapeutics stock.
At this time, Corcept Therapeutics' Net Income is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 22.2 M in 2025, whereas Non Operating Income Net Other is likely to drop slightly above 577.9 K in 2025. Corcept | Select Account or Indicator |
Corcept Therapeutics Incorporated Company Operating Margin Analysis
Corcept Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Corcept Therapeutics Operating Margin | 0.26 % |
Most of Corcept Therapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Corcept Therapeutics Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Corcept Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Corcept Therapeutics Incorporated has an Operating Margin of 0.2553%. This is 100.73% lower than that of the Pharmaceuticals sector and 100.23% lower than that of the Health Care industry. The operating margin for all United States stocks is 104.63% lower than that of the firm.
Corcept Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Corcept Therapeutics's current stock value. Our valuation model uses many indicators to compare Corcept Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Corcept Therapeutics competition to find correlations between indicators driving Corcept Therapeutics's intrinsic value. More Info.Corcept Therapeutics Incorporated is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers reporting about 0.50 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Corcept Therapeutics Incorporated is roughly 1.98 . At this time, Corcept Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Corcept Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Corcept Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corcept Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics of similar companies.Corcept Therapeutics is currently under evaluation in operating margin category among its peers.
Corcept Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corcept Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corcept Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Corcept Fundamentals
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 4.91 B | ||||
| Shares Outstanding | 104.78 M | ||||
| Shares Owned By Insiders | 11.51 % | ||||
| Shares Owned By Institutions | 85.40 % | ||||
| Number Of Shares Shorted | 15.72 M | ||||
| Price To Earning | 30.07 X | ||||
| Price To Book | 8.26 X | ||||
| Price To Sales | 8.40 X | ||||
| Revenue | 482.38 M | ||||
| Gross Profit | 396.47 M | ||||
| EBITDA | 108.32 M | ||||
| Net Income | 106.14 M | ||||
| Cash And Equivalents | 370.09 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 151 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.54 X | ||||
| Book Value Per Share | 6.10 X | ||||
| Cash Flow From Operations | 127.04 M | ||||
| Short Ratio | 19.17 X | ||||
| Earnings Per Share | 1.26 X | ||||
| Price To Earnings To Growth | 0.61 X | ||||
| Target Price | 74.9 | ||||
| Number Of Employees | 352 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 5.28 B | ||||
| Total Asset | 621.52 M | ||||
| Retained Earnings | 402.53 M | ||||
| Working Capital | 354.13 M | ||||
| Current Asset | 48.98 M | ||||
| Current Liabilities | 20.88 M | ||||
| Net Asset | 621.52 M |
About Corcept Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corcept Therapeutics Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 21.2 M | 22.3 M | |
| Total Revenue | 554.7 M | 582.5 M | |
| Cost Of Revenue | 5.8 M | 5.7 M | |
| Stock Based Compensation To Revenue | 0.12 | 0.11 | |
| Sales General And Administrative To Revenue | 182.39 | 191.51 | |
| Research And Ddevelopement To Revenue | 0.44 | 0.42 | |
| Revenue Per Share | 4.19 | 4.40 | |
| Ebit Per Revenue | 0.20 | 0.21 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.